Stay updated with breaking news from Uveitis Service. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
The biosimilar month in review highlights an interview with leading experts, the latest data regarding switching between biologics and biosimilars, and the efficacy of infliximab biosimilars among patients with inflammatory conditions.
Biosimilar infliximab-dyyb proves successful in achieving and maintaining the control of non-infectious uveitis in the study cohort.
CHICAGO (PRWEB) September 20, 2022 -- Prevent Blindness, the nation’s leading eye health and safety nonprofit organization, has declared Sept. 26 – Oct. 2,
Latest Articles New York Post ^ | August 4, 2021 | 11:40am | Mark Moore A retired top Immigration and Customs Enforcement official has announced he left the federal agency out of frustration over how the Biden administration’s border policies were jeopardizing national security — adding, “we’re pretty much screwed as a country.” Thomas Feeley, the former director for ICE in New York State, said the southern border is “wide open,” and the crisis has grown “so bad” that illegal immigrants are being processed over the phone after being released in the US. “There...